UCB S.A. (UCB or ‘the company’) is a biopharmaceutical company engaged in the research, development, manufacturing, selling and distribution of biopharmaceutical medicinal products in the fields of neurology and immunology. The company operates in about 40 countries across Europe, North America and Asia Pacific.

The company operates in one segment: Biopharmaceuticals. It develops and markets its products under two core therapeutic areas: neurology and immunology.

In the neurology category, the company markets Briviact (brivaracetam), an adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in adult and adolescent patients from 16 years of age with epilepsy; Neupro (rotigotine), a treatment for Parkinson’s disease and restless legs syndrome; Vimpat (lacosamide), a treatment for adult patients with partial onset seizures; and Keppra (levetiracetam), which is indicated for the treatment of several types of epilepsy in adults and children. In addition, the company also offers E Keppra (levetiracetam), an adjunctive therapy in the treatment of primary generalized tonicclonic seizures.

In the immunology therapy area, UCB offers Cimzia (certolizumab pegol), a tumor necrosis factor (TNF) blocker indicated for the treatment of adults with active ankylosing spondylitis. It is also indicated for the treatment of adult patients with axial spondyloarthritis, Crohn's disease, psoriatic arthritis, and rheumatoid arthritis. The company is manufacturing several drugs in the immunology therapy area, which are currently in its pipeline. For instance, in collaboration with Amgen (globally) and Astellas Pharma (in Japan), it is developing Evenity (romosozumab), an investigational bone-forming monoclonal antibody for the treatment of patients with osteoporosis. Evenity is currently in Phase III of the development pipeline. UCB in collaboration with Biogen is developing dapirolizumab pegol for the treatment of systemic lupus erythematosus. UCB is also developing Cimzia for potential treatment of children aged 2-18 years living with juvenile idiopathic arthritis.

Besides these two product categories, the company markets other products including Nootropil (piracetam) whose main indications are in the area of psycho-organic syndromes or cognitive decline and cortical myoclonus; Xyrem (sodium oxybate) for the treatment of narcolepsy with cataplexy in adult patients; Xyzal (levocetirizine), which is indicated for the treatment of allergic rhinitis, including persistent allergic rhinitis, and urticarial in adults and children over six years; and Zyrtec (cetirizine HCL), an antihistamine indicated for the symptomatic treatment of seasonal allergic rhinitis, perennial rhinitis and chronic idiopathic urticaria. In FY2016, the Biopharmaceuticals segment reported revenues of E4,178 million, which accounted for 100% of the company's total revenue.

Geographically, the company classifies its operations into 12 segments, namely the US, Germany, Japan, Spain, France (including French territories), Italy, China, the UK and Ireland, Belgium, Brazil, Europe – other (excluding Belgium), and Other Countries. In FY2016, the US segment accounted for 47.7% of the company's total net sales (excluding royalty income and fees, and other revenues), followed by Germany with 7.5%; Japan with 6.9%; Spain with 4.2%; France (including French territories) with 4.2%; Italy with 3.9%; China with 3.9%; the UK and Ireland with 3.3%; Belgium with 0.9%; Brazil with 0.8%; Europe – Other (excluding Belgium) with 8.5%; and Other Countries with 8.2%.

Scope of the Report

-- About the Company - Historical Details, Current Ownership Structure and basic overview of UCB S.A. in terms of revenue, net income, and operating income.

-- Financials - Details about UCB S.A. listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.

-- Company SWOT Analysis - Outlines UCB S.A.’s strengths, weaknesses, and opportunities and threats facing the company.

-- Recent Developments - Showcases UCB S.A.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

-- Strategic Evaluation - Provides an overview of UCB S.A.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.

Key Questions Answered

-- What domain does UCB S.A. operate and what are key points about it?

-- What is the product / service portfolio of UCB S.A.?

-- How has UCB S.A. performed financially from the 2013?

-- How does UCB S.A. rank among its peers in terms of revenue and market share?

-- What are UCB S.A. strengths and weaknesses and what opportunities and threats does it face?

-- What are UCB S.A.’s main growth strategies and how successful has the company been at implementing them?

-- What is the in-house technical capability of UCB S.A.? Where does it procure / outsource it?

Reasons to buy

-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost

-- 12 hour delivery time fulfilling your urgent requests as per your requirement

-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics